Design and In Silico and In Vitro Evaluations of a Novel Nicotinamide Derivative as a VEGFR-2 Inhibitor

Table 7

The effects of compound 10 on HepG2’s healing and migration.

	At 0 h		At 48 h		RM um	Wound closure % μm^2	Area difference %
	Area	Width	Area	Width
HepG2 cells^a	1000.34	999.38	340.6	339.53	13.74	65.961	65.983
Treated HepG2 cells^a	994.33	993.39	967.5	966.55	0.559	2.6986	2.684

^aData are presented as a mean of 5 times values.